DOCSLIB.ORG

Adverse Drug Reactions to Dopamine Agonists: a Comparative Study in the French Pharmacovigilance Database

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adverse Drug Reactions to Dopamine Agonists: a Comparative Study in the French Pharmacovigilance Database Movement Disorders Vol. 2, No. 12, 2010, pp. 1876–1880 Ó 2010 Movement Disorder Society Adverse Drug Reactions to Dopamine Agonists: A Comparative Study in the French Pharmacovigilance Database Santiago Perez-Lloret, MD, PhD,* Emmanuelle Bondon-Guitton, PharmD, PhD, Olivier Rascol, MD, PhD, Jean-Louis Montastruc, MD, PhD, and the French Association of Regional Pharmacovigilance Centers Service de Pharmacologie Clinique, EA 3696, INSERM CIC9023, UMR 825, Centre Midi-Pyre´ne´es de Pharmacovigilance, de Pharmacoe´pide´miologie et d’Information sur le me´dicament, Faculte´ de Me´decine, Centre Hospitalier Universitaire et Universite´ de Toulouse, Toulouse, France Abstract: Pharmacodynamical differences between dopamine (P < 0.001), nausea and vomiting (P < 0.05), or edemas (P agonists (DAs) suggest differences in their adverse drug reac- < 0.001). No difference among DAs was observed in the fre- tions (ADRs) profile. In this study, frequencies of ADR to quency of hallucination or arterial hypotension ADR reports DAs or levodopa reports in the French Pharmacovigilance (P 5 0.3 and P 5 0.1). Pleural effusions were more fre- Database were explored. Reports occurring between January quently reported with pergolide or bromocriptine (P < 1, 1984 and December 31, 2008 were selected (2,189 for 0.001). Somnolence or ICD reports were less frequent with DAs and 1,315 for levodopa). The numbers of ADRs by sys- levodopa, whereas confusion was more frequently reported. tem organ class were compared using ropinirole as a refer- In summary, our data show significant differences in the kind ence. Diurnal somnolence was less frequently reported with of ADRs reported for each DA. Ó 2010 Movement Disorder all DAs when compared with ropinirole (P < 0.001). Impulse Society control disorders (ICDs) were more frequently reported with Key words: dopamine agonists; adverse drug reactions; pramipexole (P < 0.001). Significant difference was found pharmacovigilance; ropinirole; pramipexole; bromocriptine; among DAs in the frequency of confusion or disorientation pergolide; apomorphine Dopamine agonists (DAs) are indicated in Parkin- Significant differences in the frequency of adverse son’s disease (PD), restless leg syndrome (RLS), or events to DAs were found during randomized clinical hyperprolactinemia.1 DAs exhibit important differences trials (RCTs) in PD or RLS.4,5 Although frequencies of in pharmacodynamic properties.2 Ergot DAs (i.e., bro- somnolence, hallucination, or anxiety cases were higher mocriptine, cabergoline, lisuride, and pergolide) have with nonergot DAs, incidence of vomiting, arterial hy- higher affinities for the 5-HT1 and 5-HT2 receptors potension, or depression was higher with ergots. Prami- than nonergot DAs (i.e., apomorphine, quinagolide, pra- pexole in RLS induced less nausea, vomiting, or dizzi- mipexole, piribedil, and ropinirole). Pramipexole has a ness than ropinirole. Other observational studies showed higher selectivity for the D2-like family, followed by that frequency of valvular heart disease in PD was ropinirole, and then by ergot DAs. D3/D2 receptor higher with ergot when compared with nonergot DAs.6 selectivity is pramipexole > ropinirole > ergot DAs. All this findings suggest possible differences in the Ergot DAs are also alpha-adrenoceptor antagonists.3 safety profile of the DAs. To further explore these differ- ences, we compared the frequency of adverse drug reac- tion (ADR) reports to the French pharmacovigilance sys- tem between the DAs currently available in France. *Correspondence to: Dr. Santiago Perez-Lloret, Department of Clinical Pharmacology, Faculty of Medicine, 37 Alle´es Jules Guesde, 31000 Toulouse, France. E-mail: splloret@fleni.org.ar METHODS Potential conflict of interest: Nothing to report. Received 7 December 2009; Revised 11 March 2010; Accepted 1 Source of Data April 2010 Published online 28 July 2010 in Wiley Online Library The French pharmacovigilance system was first (wileyonlinelibrary.com). DOI: 10.1002/mds.23204 established in 1973 and consists of a network of 31 re- 1876 ADRs TO DOPAMINE AGONISTS IN THE FPD 1877 gional centers. The French Pharmacovigilance Database RESULTS (FPD) was established in 1985 to record spontaneous Between 1984 and 2008, 2,189 ADRs in which at 7 reporting of ADRs, while reporting ‘‘serious’’ or ‘‘unla- least one AD or 1,315 in which L-dopa was suspected 8 beled’’ ADRs has been mandatory since 1995. A ‘‘seri- were reported to the French pharmacovigilance system ous’’ ADR is defined as any untoward medical occur- (Table 1). Gender distribution of cases was 50/50 for rence that at any dose results in death, requires hospital drugs not used in hyperprolactinemia. On the contrary, admission or prolongation of existing hospital stay, for cabergoline, quinagolide, lisuride, or bromocriptine, resultsinpersistentorsignificantdisability/incapacity, female cases prevailed when compared with other DAs 9 or is life threatening. Spontaneous reports submitted to (65 vs. 50%, P < 0.03). the FPD, in which the products containing any DA were Total and by-drug ADRs frequencies according to 9 ‘‘suspected’’ as defined by WHO, independently from ‘‘seriousness’’ or organ class are shown in Table 1. Com- the level of imputability, were extracted from January 1, parisons of ADR frequency most commonly associated 1984 (date of first report of an ADR to DAs) to Decem- with DAs (according to the system organ class) are shown ber 31, 2008. ADRs to levodopa (L-dopa) were also an- in Table 2. Diurnal somnolence was less frequently alyzed. Total number of ADRs, number of ‘‘serious’’ reported with all DAs or L-dopa when compared with ADRs, and number of ADRs by system organ class ropinirole. Results remained unchanged when the study (according to the Medical Dictionary for Drug Regula- 1 period was split in two subperiods: January 1984 to De- tory Activities ) were compared between the DAs cur- cember 1999 and January 2000 to December 2008. rently marketed in France. Information about DAs dose ICDs (i.e., hypersexuality, compulsive shopping, eat- was not systematically collected in this work. ing, or gambling) were more frequently reported with In France, apomorphine, bromocriptine, lisuride, per- pramipexole and less with bromocriptine or L-dopa. golide, piribedil, pramipexole, or ropinirole are mar- Results remained unchanged when the study period keted as antiparkinsonian drugs and bromocriptine, was split in two subperiods: January 1984 to December cabergoline, lisuride, or quinagolide for hyperprolacti- 2000 and January 2001 to December 2008. nemia. Pramipexole and ropinirole are the two sole Edemas were less frequently reported with L-dopa 1 DAs marketed for RLS. Ropinirole was used as the when compared with ropinirole. Although a significant referential DA as it is nowadays the most commonly difference could be noticed among DAs in the fre- used DA for the treatment of PD and RLS in France. quency of confusion and disorientation (P < 0.001), 10 Notoriety biases could be suspected for some ADRs nausea and vomiting (P < 0.05), no single comparison to DAs: (1) cardiac valvulopathies could have been yielded significant differences with ropinirole. Cardiac reported more frequently with pergolide when compared valvulopathy was significantly more frequently with the other DAs after the Lilly France ‘‘Dear Doctor reported with pergolide when compared with ropinir- 11 Letter’’ in September 2003; (2) excessive diurnal som- ole. All cases of cardiac valvulopathies were reported nolence reactions reported to nonergolinic DAs could after September 2003. Pleural effusion was more fre- have been prompted by Frucht et al. initial reports in quently reported with bromocriptine or pergolide, with- 12 13 1999 ; and (3) Giovannoni et al. findings in 2000 could out differences between the periods January 1984 to have boosted the exploration of impulse control disorders September 2003 and October 2003 to December 2008. (ICDs). The effect of these potential biases was explored by dividing the studied 24-year time span in shorter peri- ods according to the different dates of these safety alerts. DISCUSSION In this study, significant differences in the type of Statistical Analysis ADRs reported to the French pharmacovigilance sys- Categorical variables were compared using chi- tem according to the different DAs were found, provid- square or Fisher exact test when appropriate. To avoid ing further evidence about possible differences in the alpha error inflation when comparing ADRs frequen- safety profile of the DAs. cies between DAs, test-wise alpha error was set at Our study suffers from some mandatory limitations. 0.006. Thus, experiment-wise alpha error remained First, underreporting of ADRs to pharmacovigilance below the desired 0.05 level. Odds ratio and 99.3% system is usual and may reach 90% of cases.14 None- confidence interval were calculated for each DA using theless, underreporting rate was shown to be similar ropinirole as a reference. Statistical analyses were per- for several drugs from the same therapeutic class,15 formed using Epi Info Version 6. and this methodology was further validated by our Movement Disorders, Vol. 25, No. 12, 2010 1878 S. PEREZ-LLORET ET AL. Movement Disorders, Vol. 25, No. 12, 2010 TABLE 1. Frequency of ADRs (according to the system organ class) reported with DAs to the French pharmacovigilance system between 1984 and 2008 ‘‘Serious’’ Neuropsychiatric, General, Cutaneous, Gastrointestinal, Vascular, Cardiac, Respiratory/Mediastinic, Metabolic, Ocular, ADRs, N 5 1,163 N 5 861 N 5 423 N 5
Load more

Recommended publications
  • Pericardial, Retroperitoneal, and Pleural Fibrosis Induced by Pergolide
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.66.1.79 on 1 January 1999. Downloaded from J Neurol Neurosurg Psychiatry 1999;66:79–81 79 SHORT REPORT Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide S Shaunak, A Wilkins, J B Pilling, D J Dick Abstract 1992, the emergence of motor fluctuations led Three patients with Parkinson’s disease to the introduction of pergolide, and the dose are described who developed pericardial, of this was gradually increased to a maximum retroperitoneal, and pleural fibrosis asso- of 1mg/day. 1n 1994, 2 years after the ciated with pergolide treatment. Surgical introduction of pergolide, the patient devel- intervention was required in all three oped left flank pain with weight loss, and was cases, either to reach a tissue diagnosis or found to have a mild anaemia (haemoglobin for potentially life threatening complica- 10.4 g/dl), with indices suggesting iron defi- tions. Symptoms emerged on average 2 ciency, and an ESR of 40 mm/h. Upper gastro- years after the institution of treatment, intestinal endoscopy and barium enema gave and were suYciently non-specific to cause negative results. Seven months later right sided significant delays in diagnosis in all cases. chest pain and a non-productive cough devel- The erythrocyte sedimentation rate (ESR) oped; investigations confirmed persistent anae- was raised in the two patients in whom it mia, an ESR of 55 mm/h, and bilateral pleural was measured. Serosal fibrosis is a rarely thickening on chest radiography and CT. Lung reported adverse eVect of pergolide treat- function tests showed a reduction in total lung ment, although it is well described with capacity of 36% with no fall in transfer factor, other dopamine agonists.
    [Show full text]
  • Evidence from Horses with Pituitary Pars Intermedia Dysfunction Jessica S
    Fortin et al. BMC Veterinary Research (2020) 16:356 https://doi.org/10.1186/s12917-020-02565-3 RESEARCH ARTICLE Open Access Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction Jessica S. Fortin1*, Matthew J. Benskey2, Keith J. Lookingland2, Jon S. Patterson1, Erin B. Howey1, John L. Goudreau2,3 and Harold C. Schott II4* Abstract Background: Pituitary pars intermedia dysfunction (PPID) develops slowly in aged horses as degeneration of hypothalamic dopaminergic neurons leads to proliferation of pars intermedia (PI) melanotropes through hyperplasia and adenoma formation. Dopamine (DA) concentrations and tyrosine hydroxylase (TH) immunoreactivity are markedly reduced in PI tissue of PPID-affected equids and treatment with the DA receptor agonist pergolide results in notable clinical improvement. Thus, we hypothesized that pergolide treatment of PPID-affected horses would result in greater DA and TH levels in PI tissue collected from PPID-affected horses versus untreated PPID-affected horses. To test this hypothesis, pituitary glands were removed from 18 horses: four untreated PPID-affected horses, four aged and four young horses without signs of PPID, and six PPID-affected horses that had been treated with pergolide at 2 µg/kg orally once daily for 6 months. DA concentrations and TH expression levels in PI tissues were determined by high performance liquid chromatography with electrochemical detection and Western blot analyses, respectively. Results: DA and TH levels were lowest in PI collected from untreated PPID-affected horses while levels in the pergolide treated horses were similar to those of aged horses without signs of PPID.
    [Show full text]
  • WO 2014/106238 Al 3 July 2014 (03.07.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/106238 Al 3 July 2014 (03.07.2014) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/404 (2006.01) C07D 209/04 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61P 25/18 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (21) International Application Number: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, PCT/US2013/078453 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 3 1 December 2013 (3 1.12.2013) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (25) Filing Language: English ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/747,499 31 December 2012 (3 1. 12.2012) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicant: FANG, Qun, Kevin [US/US]; 34 Atwood TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Street, Westfield, MA 02482 (US).
    [Show full text]
  • Progress and Prospects of Ergot Alkaloid Research
    Progress and Prospects of Ergot Alkaloid Research Joydeep Mukherjee, Miriam Menge Institut für Technische Chemie, Universität Hannover, Callinstr. 3, D-30167 Hannover, Germany E-mail: [email protected] Ergot alkaloids, produced by the plant parasitic fungi Claviceps purpurea are important pharmaceuticals. The chemistry, biosynthesis, bioconversions, physiological controls, and biochemistry have been extensively reviewed by earlier authors.We present here the research done on the organic synthesis of the ergot alkaloids during the past two decades. Our aim is to apply this knowledge to the synthesis of novel synthons and thus obtain new molecules by directed biosynthesis. The synthesis of clavine alkaloids, lysergic acid derivatives, the use of tryptophan as the starting material, the chemistry of 1,3,4,5-tetrahydrobenzo[cd]indoles, and the structure activity relationships for ergot alkaloids have been discussed. Recent advances in the molecular biology and enzymology of the fungus are also mentioned. Application of oxygen vectors and mathematical modeling in the large scale production of the alkaloids are also discussed. Finally, the review gives an overview of the use of modern analytical methods such as capillary electrophoresis and two-dimensional fluorescence spectroscopy. Keywords. Ergot, Alkaloid synthesis, Claviceps, Directed biosynthesis, Bioreactors 1Introduction . 2 2 Chemistry, Bioconversions, and Directed Biosynthesis . 2 2.1 Chemical Synthesis . 3 2.1.1 Chemical Structures . 3 2.1.1.1 Clavine Alkaloids . 3 2.1.1.2 Simple Lysergic Acid Derivatives . 4 2.1.1.3 Ergopeptines . 4 2.1.1.4 Ergopeptams . 5 2.1.2 Synthesis of Clavine Alkaloids and Lysergic Acid Derivatives . 5 2.1.3 Use of Tryptophan as the Starting Material .
    [Show full text]
  • Biased Ligands Differentially Shape the Conformation of The
    International Journal of Molecular Sciences Article Biased Ligands Differentially Shape the Conformation of the Extracellular Loop Region in 5-HT2B Receptors Katrin Denzinger, Trung Ngoc Nguyen, Theresa Noonan, Gerhard Wolber and Marcel Bermudez * Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Strasse 2-4, 14195 Berlin, Germany; [email protected] (K.D.); [email protected] (T.N.N.); [email protected] (T.N.); [email protected] (G.W.) * Correspondence: [email protected] Received: 22 November 2020; Accepted: 18 December 2020; Published: 20 December 2020 Abstract: G protein-coupled receptors are linked to various intracellular transducers, each pathway associated with different physiological effects. Biased ligands, capable of activating one pathway over another, are gaining attention for their therapeutic potential, as they could selectively activate beneficial pathways whilst avoiding those responsible for adverse effects. We performed molecular dynamics simulations with known β-arrestin-biased ligands like lysergic acid diethylamide and ergotamine in complex with the 5-HT2B receptor and discovered that the extent of ligand bias is directly connected with the degree of closure of the extracellular loop region. Given a loose allosteric coupling of extracellular and intracellular receptor regions, we delineate a concept for biased signaling at serotonin receptors, by which conformational interference with binding pocket closure restricts the signaling repertoire of the receptor. Molecular docking studies of biased ligands gathered from the BiasDB demonstrate that larger ligands only show plausible docking poses in the ergotamine-bound structure, highlighting the conformational constraints associated with bias. This emphasizes the importance of selecting the appropriate receptor conformation on which to base virtual screening workflows in structure-based drug design of biased ligands.
    [Show full text]
  • Prascend® (Pergolide Tablets)1 Mg
    PRASCEND- pergolide tablet Boehringer Ingelheim Animal Health USA Inc. ---------- Prascend® (pergolide tablets) 1 mg Dopamine receptor agonist for oral use in horses only Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Description: PRASCEND Tablets are rectangular light red colored, half-scored tablets containing 1 mg pergolide, as pergolide mesylate. Pergolide mesylate is a synthetic ergot derivative and is a potent dopamine receptor agonist. The chemical name of pergolide mesylate is 8β-[(Methylthio) methyl]-6- propylergoline monomethanesulfonate. The chemical structure is: Indication: For the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease) in horses. Dosage and Administration: Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily. It has been reported that pergolide tablets may cause eye irritation, an irritating smell, or headache when PRASCEND Tablets are split or crushed. PRASCEND Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets. The tablets are scored and the calculated dosage should be provided to the nearest one-half tablet increment (see Table 1). Table 1 Dosing Table Dosage Dosage Body Weight 2 mcg/kg 4 mcg/kg 136 - 340 kg 0.5 tablet 1 tablet (300 - 749 lb) 341 - 567 kg 1 tablet 2 tablets (750 - 1,249 lb) 568 - 795 kg 1.5 tablets 3 tablets (1,250 - 1,749 lb) 796 - 1,022 kg 2 tablets 4 tablets (1,750 - 2,249 lb) Dosing should be titrated according to individual response to therapy to achieve the lowest effective dose.
    [Show full text]
  • WO 2010/099522 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 September 2010 (02.09.2010) WO 2010/099522 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/4164 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4045 (2006.01) A61K 31/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2010/025725 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 1 March 2010 (01 .03.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/156,129 27 February 2009 (27.02.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, HELSINN THERAPEUTICS (U.S.), INC.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Zirtek Plus Decongestant 5mg/120mg Prolonged Release Tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet provides 5 mg cetirizine dihydrochloride for immediate release, and 120 mg pseudoephedrine hydrochloride for prolonged release. Excipients with known effect: one tablet contains 43.23 mg lactose monohydrate For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Prolonged release tablet. White to off-white, round, biconvex circle-embossed, film-coated tablet, having a circular logo on one side. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Cetirizine-pseudoephedrine is indicated for the treatment of symptoms such as nasal congestion, sneezing, rhinorrhoea, and nasal and ocular pruritus associated with seasonal or perennial allergic rhinitis. Cetirizine-pseudoephedrine should be administered when the anti-allergic properties of cetirizine dihydrochloride and the nasal decongestant activity of pseudoephedrine hydrochloride are desired. 4.2 Posology and method of administration Posology Adults One tablet two times a day (morning and evening), corresponding to the maximum recommended dose of 10 mg of cetirizine dihydrochloride and 240 mg of pseudoephedrine hydrochloride daily. Special populations Paediatric population Adolescents from 12 years of age and above: 1 tablet two times a day (morning and evening), with or without food. Children under 12 years of age: the use of the product is contraindicated (see sections 4.3 and 4.4). Renal impairment The dose should be reduced to 1 tablet daily in patients with moderate renal insufficiency. Hepatic impairment The dose should be reduced to 1 tablet daily in patients with moderate hepatic insufficiency.
    [Show full text]
  • Hyperprolactinaemia: a Monster Between the Woman and Her Conception *Seriki A
    Archives of Reproductive Medicine and Sexual Health ISSN: 2639-1791 Volume 1, Issue 2, 2018, PP: 61-67 Hyperprolactinaemia: A Monster Between the Woman and Her Conception *Seriki A. Samuel1, Odetola O. Anthony2 1Department of Human Physiology, College of Medicine, Bingham University, Karu, Nigeria. 2Department of Human Physiology, College Medical Sciences, NnamdiAzikwe University, Awka, Nigeria. [email protected] *Corresponding Author: Seriki A. Samuel, Department of Human Physiology, College of Medicine, Bingham University, Karu, Nigeria. Abstract Hyperprolactinaemia is the presence of abnormally high levels of prolactin in the blood. Normal levels are less than 5000 ml U/L [20ng/mL or µg/L] for women, and less than 450 ml U/L for men.Prolactin is a peptide hormone produced by the adenohypophysis (also called anterior pituitary) that is primarily associated with milk production and plays a vital role in breast development during pregnancy. Hyperprolactinaemia may cause galactorrhea (production and sp; ontaneous ejection of breast milk without pregnancy or childbirth). It also alters/disrupts the normal menstrual cycle in women. In other women, menstruation may cease completely, resulting in infertility. In the man, it could causeerectile dysfunction.The present study is to review the pathophysiology of the abnormality in the woman, and how it relates to the functioning of the hypothalamo- hypophyseal-gonadal system. The article also looks at the effect of hyperprolactinaemia on the fertility of the woman, and attempts to proffer non-surgical remedy to the condition. Keywords: Galactorrhea, adenohypophysis,hypoestrogenism,prolactinoma, amenorrhoea, macroprolactin, microprolactin Introduction It is synthesized by the anterior pituitary lactotrophs and regulated by the hypothalamic–pituitary axis Hyperprolactinaemia, which is a high level of through the release of dopamine, which acts as a prolactin in the blood can be a part of normal prolactin inhibitory factor[2].
    [Show full text]
  • USP Reference Standards Catalog
    Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction 1000408 Abacavir Sulfate R028L0 F1L487 (12/16) 188062-50-2 $222.00 (200 mg) 1000419 Abacavir Sulfate F0G248 188062-50-2 $692.00 Racemic (20 mg) (4-[2-amino-6-(cyclo propylamino)-9H-pur in-9yl]-2-cyclopenten e-1-methanol sulfate (2:1)) 1000420 Abacavir Related F1L311 F0H284 (10/13) 124752-25-6 $692.00 Compound A (20 mg) ([4-(2,6-diamino-9H- purin-9-yl)cyclopent- 2-enyl]methanol) 1000437 Abacavir Related F0M143 N/A $692.00 Compound D (20 mg) (N6-Cyclopropyl-9-{( 1R,4S)-4-[(2,5-diami no-6-chlorpyrimidin- 4-yloxy)methyl] cyclopent-2-enyl}-9H -purine-2,6-diamine) 1000441 Abacavir Related F1L318 F0H283 (10/13) N/A $692.00 Compound B (20 mg) ([4-(2,5-diamino-6-c Page 1 Last Updated On: January 6, 2016 USP Reference Standards Catalog Catalog # Description Current Lot Previous Lot CAS # NDC # Unit Price Special Restriction hloropyrimidin-4-yla mino)cyclopent-2-en yl]methanol) 1000452 Abacavir Related F1L322 F0H285 (09/13) 172015-79-1 $692.00 Compound C (20 mg) ([(1S,4R)-4-(2-amino -6-chloro-9H-purin-9 -yl)cyclopent-2-enyl] methanol hydrochloride) 1000485 Abacavir Related R039P0 F0J094 (11/16) N/A $692.00 Compounds Mixture (15 mg) 1000496 Abacavir F0J102 N/A $692.00 Stereoisomers Mixture (15 mg) 1000500 Abacavir System F0J097 N/A $692.00 Suitability Mixture (15 mg) 1000521 Acarbose (200 mg) F0M160 56180-94-0 $222.00 (COLD SHIPMENT REQUIRED) 1000532 Acarbose System F0L204 N/A $692.00 Suitability
    [Show full text]
  • Effect of Dietary Exposure to Ergot Alkaloids on Contractility of Bovine Mesenteric Vasculature and Rumen Motility
    University of Kentucky UKnowledge Theses and Dissertations--Animal and Food Sciences Animal and Food Sciences 2014 EFFECT OF DIETARY EXPOSURE TO ERGOT ALKALOIDS ON CONTRACTILITY OF BOVINE MESENTERIC VASCULATURE AND RUMEN MOTILITY Amanda M. Egert University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Egert, Amanda M., "EFFECT OF DIETARY EXPOSURE TO ERGOT ALKALOIDS ON CONTRACTILITY OF BOVINE MESENTERIC VASCULATURE AND RUMEN MOTILITY" (2014). Theses and Dissertations--Animal and Food Sciences. 40. https://uknowledge.uky.edu/animalsci_etds/40 This Master's Thesis is brought to you for free and open access by the Animal and Food Sciences at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Animal and Food Sciences by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]